FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $529.68M | ||||
Company | Location |
Date | Amt. (M) |
Details |
Achaogen Inc. |
South San Francisco |
10/10/06 |
$26 |
New investor Domain Venture Partners led the Series B round, which also included Series A investors 5AM Ventures, ARCH Venture Partners, Venrock Associates and Versant Ventures |
Action Pharma |
Stockholm, Sweden | 10/27/06 |
€6 ($7.7) |
Investing in the financing round were Innovations Kapital, Growth Foundation and Incuba Ventures; they have an option to invest an additional €3M |
Affectis |
Munich, Germany |
10/24/06 |
€12 ($15.1) |
The Series C financing was led by new investor Aescap Venture, and included all existing investors |
Amorcyte |
Hackensack, N.J. |
10/23/06 |
ND |
An undisclosed investment was added to a $4.2M Series A round completed in June; PA Early Stage Partners placed the additional financing |
Amsterdam |
Amsterdam, the Netherlands |
10/4/06 |
€22 ($27.7) |
The Series A financing was led by ABN AMRO Capital Life Sciences, and included Advent Venture Partners, Gilde Healthcare Partners and Credit Agricole Private Equity |
Amyris |
Emeryville, Calif. |
10/12/06 |
$20 |
The Series A financing was led by Khosla Ventures, and included Kleiner Perkins Caufield & Byers and Texas Pacific Group Ventures |
Applied |
Freeport, N.Y. |
10/10/06 |
$5.5 |
Trevi Health Ventures led the Series A round, which included WHI Group and other investors |
Cempra |
Research Triangle Park, N.C. |
10/3/06 |
$8 |
The company's Series A financing round of $14M in August was increased to $22M, as Aisling Capital joined two other firms as a co-lead investor |
CMP |
Oxford, UK |
10/23/06 |
€4.5 ($5.7) |
The Series A financing is being provided in tranches by Inventages Capital Investments Inc. |
CoDa |
San Diego |
10/10/06 |
$10 |
The Series A financing was provided by Domain Associates; the company anticipated another $5M to $10M investment within 90 days |
Cytheris SA |
Paris |
10/25/06 |
€24.3 ($30.9) |
CDC Enterprises Innovation led the Series B round, which included ABN AMRO Capital Life Sciences, AXA Private Equity, BIOAM/Bioamgestion, Crédit Agricole Private Equity, T2C2/Bio 2000 and Caisse de Dépôt et Placement du Québec |
Diffusion |
Charlottesville, Va. |
10/17/06 |
$1.5 |
The financing came primarily from existing shareholders |
EnVivo |
Watertown, Mass. |
10/4/06 |
$24 |
The Series C financing was led by existing investor Fidelity Biosciences, which also led the Series A and B rounds |
Esperance |
Baton Rouge, La. |
10/31/06 |
$9 |
The Series A financing was co-led by Louisiana Fund I, Themelios Ventures Partners LP and Research Corp. Technologies Inc. |
Faust |
Strasbourg, France |
10/9/06 ($10.3) |
€8.2 |
Funding was the first tranche of what was expected to be a Series C round of up to €35M; investors were Sofinnova Partners, Auriga Partners, Siparex Ventures, Edmond de Rothschild Investment Partners, AGF Private Equity and CDC Entreprises - FCJE |
Heidelberg |
Ladenburg, Germany |
10/2/06 |
€16 ($20) |
HDP Beteiligungs GmbH invested €16M in the Series B round, increasing its stake in the company to about 86% |
Macroflux |
Mountain View, Calif. |
10/10/06 |
$75 |
The Alza Corp. spin-out completed its initial funding, with an investment led by Nomura Phase4 Ventures and including New Enterprise Associates and funds managed by HBM Partners |
Morphotek |
Exton, Pa. |
10/12/06 |
$40 |
The Series D financing was led by Investor Growth Capital and included new investors MDS Capital and Hunt BioVentures and existing investors Forward Ventures, Morgenthaler Ventures, SR One, Flagship Ventures, Burrill & Co., CB Health Ventures and Rock Maple Ventures |
MTM |
Heidelberg, Germany |
10/9/06 |
€22 ($27.6) |
The Series C financing was led by HBM Bio- Ventures and HBM BioCapital, and included Heidelberg Innovation, Wellington Partners, Nexus Medical Partners and SwissFirst Bank |
NovImmune |
Geneva |
10/30/06 |
CHF58 ($46.6) |
The Series B financing round was led by new investor BZ Bank and included Pictet Private Equity Investors SA, along with existing investors Lombard Odier Darier Hentsch, Novartis Venture Fund and Aravis Venture |
Pharmaxon |
Marseilles, France |
10/3/06 |
€0.5 ($0.63) |
Participating in the seed funding round were Inserm Transfert Initiative, Esperante, Primaveris and CAAP Creation |
Portola |
South San Francisco |
10/17/06 |
$20 |
Hercules Technology Growth Capital Inc. provided $20M of debt financing to Portola |
ProNAi |
Kalamazoo, Mich. |
10/24/06 |
$6.65 |
The bridge funding round included investments from Apjohn Ventures, Grand Angels, Amherst Fund, Sigvion Ventures and an earlier investment of $3.3M from the Michigan Economic Development Corp. |
Santhera |
Liestal, Switzerland |
10/5/06 |
€10 ($12.8) |
The financing was led by existing investor NGN Capital and included new investors NeoMed Management, Schroder Investment Management SA and BioMedinvest, and existing investors Carnegie Asset Management, GIMV, Dow Chem- ical, Clariden Biotechnology Fund, 3i and others; Santhera has an additional €5M call option |
Tacere |
San Jose, Calif. |
10/12/06 |
ND |
The seed financing was provided by Hokkaido Venture Capital |
VaxInnate |
Cranbury, N.J. |
10/25/06 |
$40 |
The Series C financing was led by New Leaf Venture Partners and included Canaan Partners, as well as existing investors HealthCare Ventures, Oxford Bioscience Partners LLC, MedImmune Ventures Inc. and CHL Medical Partners |
Xencor Inc. |
Monrovia, Calif. |
10/18/06 |
$39 |
The Series E financing was led by MedImmune Ventures Inc. and included new investors Novo Nordisk and HealthCare Ventures, as well as existing investor Zen Investments; the $39M total does not include a $6M bridge investment that previously was disclosed |
Notes: | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
ND = Not disclosed. | ||||
To read more on related topics, click on one of the words below.